Acadia Pharmaceuticals Inc (NASDAQ:ACAD) finished Friday with a subtraction of -$0.69 to close at $20.84, a downside of -3.20 percent. An average of 3,912,100 shares of common stock have been traded in the last five days. There was a fall of -$2.72 in the past week, and it reached a new high 26 times over the past 12 months. The last 20 days have seen an average of 1,963,870 shares traded, while the 50-day average volume stands at 1,714,928.
ACAD stock has decreased by -22.79% in the last month. The company shares reached their 1-month lowest point of $20.54 on 09/29/23. With the stock rallying to its 52-week high on 07/18/23, shares of the company touched a low of $13.73 and a high of $33.99 in 52 weeks. It has reached a new high 27 times so far this year and achieved 30.90% or $4.92 in price. In spite of this, the price is down -38.69% from the 52-week high.
Insider Transactions
ACAD stock investors should be aware that Acadia Pharmaceuticals Inc (ACAD) stock had its last reported insider trading activity 15 days ago on Sep 15. In this transaction, the insider spent $51,760. EVP, Chief Financial Officer, Schneyer Mark C., disposed of 10,000 shares at a price of $29.00 on Aug 21. The insider now owns more than $289,970 worth of shares. Prior to that, CEO DAVIS STEPHEN went on to Sale 100,000 shares at $30.04 each on Jul 14. An amount of $3,004,350 was transacted.
Valuation Metrics
Acadia Pharmaceuticals Inc (ACAD) stock’s beta is 0.64. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.19, the price-to-book (PB) ratio at 8.60.
Financial Health
The quick ratio of Acadia Pharmaceuticals Inc for the three months ended June 29 was 2.57, and the current ratio was 2.62, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.13 and a total debt to equity ratio of 0.15 for the quarter ending June 29. Its gross profit as reported stood at $507.07 million compared to revenue of $517.24 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.11 million in the quarter, while revenues were grew 3163.96%. The analyst consensus anticipated Acadia Pharmaceuticals Inc’s latest quarter earnings to come in at -$0.08 per share, but it turned out to be $0.01, a 112.50% surprise. For the quarter, EBITDA amounted to $3.31 million. Shareholders own equity worth $163.73 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Acadia Pharmaceuticals Inc (ACAD) price momentum. RSI 9-day as of the close on 29 September was 26.85%, suggesting the stock is oversold, with historical volatility in this time frame at 98.87%.
As of today, ACAD’s price is $22.97 -11.54% or -$2.72 from its 5-day moving average. ACAD is currently trading -22.87% lower than its 20-day SMA and -3.29% lower than its 100-day SMA. However, the stock’s current price level is -33.33% below the SMA50 and +34.36% above the SMA200.
The stochastic %K and %D were 24.23% and 26.78%, respectively, and the average true range (ATR) was 1.39. With the 14-day stochastic at 4.55% and the average true range at 1.23, the RSI (14) stands at 29.10%. The stock has reached -0.69 on the 9-day MACD Oscillator while the 14-day reading was at -1.43.
Analyst Ratings
Guggenheim upgraded Acadia Pharmaceuticals Inc (NASDAQ: ACAD) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Acadia Pharmaceuticals Inc (ACAD) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell ACAD, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is ACAD’s price target for the next 12 months?
Analysts predict a range of price targets between $13.00 and $42.00, with a median target of $33.00. Taking a look at these predictions, the average price target given by analysts for Acadia Pharmaceuticals Inc (ACAD) stock is $31.93.
